Effect of Mesenchymal Stem Cells and Chicken Embryo Extract on Flap Viability and Mast Cells in Rat Skin Flaps

2018 ◽  
Vol 33 (2) ◽  
pp. 123-133 ◽  
Author(s):  
Farzaneh Chehelcheraghi ◽  
Mohammad Bayat ◽  
Sufan Chien
Microsurgery ◽  
2015 ◽  
Vol 36 (5) ◽  
pp. 402-409 ◽  
Author(s):  
Osman Kelahmetoglu ◽  
Rukiye Demir ◽  
Gulsen Okten ◽  
Ahmet Demir ◽  
Ferda Alpaslan Pinarli ◽  
...  

2021 ◽  
Author(s):  
Namhee Jung ◽  
TaeHo Kong ◽  
Yeonsil Yu ◽  
Hwanhee Park ◽  
Eunjoo Lee ◽  
...  

Abstract Human mesenchymal stem cells (MSCs) are emerging as a treatment for atopic dermatitis (AD), which is a common inflammatory skin disorder that affects a large number of people across the world. Treatment of AD using human umbilical cord blood-derived MSCs (hUCB-MSCs) has recently been studied; however, the mechanism underlying the effects of these cells is unclear. This study investigated the effect of epidermal growth factor (EGF) secreted by hUCB-MSCs on AD. hUCB-MSCs secreted a high concentration of EGF compared with other cell types. To elucidate the effect of EGF secreted by hUCB-MSCs, EGF expression was downregulated in hUCB-MSCs using EGF-targeting small interfering RNA, and these cells were co-cultured with keratinocytes, Th2 cells, and mast cells. Depletion of EGF expression disrupted the immunomodulatory effects of hUCB-MSCs on these AD-related inflammatory cells. In a Dermatophagoides farinae-induced AD mouse model, subcutaneous injection of hUCB-MSCs ameliorated gross scoring, histopathologic damage, and mast cell infiltration, and significantly reduced the levels of inflammatory cytokines including interleukin (IL)-4, tumor necrosis factor-α (TNFa), thymus and activation-regulated chemokine (TARC), and IL-22, as well as the serum IgE level. These therapeutic effects were significantly attenuated at all evaluation points in mice injected with EGF-depleted hUCB-MSCs. Taken together, these results suggest that EGF secreted by hUCB-MSCs plays an important role in treatment of AD by regulating the inflammatory response in keratinocytes, Th2 cells, and mast cells.


2016 ◽  
Vol 94 ◽  
pp. 32-42 ◽  
Author(s):  
Mansoreh Nazari ◽  
Nathan C. Ni ◽  
Ana Lüdke ◽  
Shu-Hong Li ◽  
Jian Guo ◽  
...  

2019 ◽  
Vol 20 (11) ◽  
pp. 2646 ◽  
Author(s):  
Federica Facchin ◽  
Francesco Alviano ◽  
Silvia Canaider ◽  
Eva Bianconi ◽  
Martina Rossi ◽  
...  

Stem cells undergo senescence both in vivo, contributing to the progressive decline in self-healing mechanisms, and in vitro during prolonged expansion. Here, we show that an early developmental zebrafish embryo extract (ZF1) could act as a modulator of senescence in human mesenchymal stem cells (hMSCs) isolated from both adult tissues, including adipose tissue (hASCs), bone marrow (hBM-MSCs), dental pulp (hDP-MSCs), and a perinatal tissue such as the Wharton’s Jelly (hWJ-MSCs). In all the investigated hMSCs, ZF1 decreased senescence-associated β-galactosidase (SA β-gal) activity and enhanced the transcription of TERT, encoding the catalytic telomerase core. In addition, it was associated, only in hASCs, with a transcriptional induction of BMI1, a pleiotropic repressor of senescence. In hBM-MSCs, hDP-MSCs, and hWJ-MSCs, TERT over-expression was concomitant with a down-regulation of two repressors of TERT, TP53 (p53), and CDKN1A (p21). Furthermore, ZF1 increased the natural ability of hASCs to perform adipogenesis. These results indicate the chance of using ZF1 to modulate stem cell senescence in a source-related manner, to be potentially used as a tool to affect stem cell senescence in vitro. In addition, its anti-senescence action could also set the basis for future in vivo approaches promoting tissue rejuvenation bypassing stem cell transplantation.


2021 ◽  
Author(s):  
Chenzhen Zhang ◽  
Tie-Jun Yuan ◽  
Min-Hong Tan ◽  
Xue-Han Xu ◽  
Yan-Fen Huang ◽  
...  

Strategies to direct the differentiation of endogenous bone marrow derived mesenchymal stem cells (BMSCs) in vivo following recruitment to the injured site are critical to realizing the potential of stem cell-based therapies.


2018 ◽  
Vol 22 (5) ◽  
pp. 322-330 ◽  
Author(s):  
Farzaneh Chehelcheraghi ◽  
Abolfazl Abbaszadeh ◽  
Magid Tavafi ◽  
◽  
◽  
...  

2013 ◽  
Vol 1 (3) ◽  
pp. e22 ◽  
Author(s):  
Koichi Tomita ◽  
Akimitsu Nishibayashi ◽  
Kenji Yano ◽  
Ko Hosokawa

Sign in / Sign up

Export Citation Format

Share Document